Skip to main content
Premium Trial:

Request an Annual Quote

Metamark, Definiens Partner on Cancer Dx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metamark Genetics and Definiens today announced that they are collaborating on the development and commercialization of a multiplex platform that will run prognostic and predictive assays for early-stage cancers.

The collaboration will combine Metamark's multiplex protein detection platform with image analysis technology that the Cambridge, Mass.-based firm will jointly develop with Munich, Germany-based Definiens. The firms said that Metamark's quantitative diagnostic approach can "identify and account for small regions of molecularly aggressive cancer cells within an otherwise indolent tumor."

Financial and other terms of the alliance were not disclosed.

"The capability to provide detailed readouts from tissue analysis is opening up new gateways for developing diagnostic assays as we enter the age of personalized medicine," Thomas Colarusso, VP of sales and operations for Definiens, said in a statement. "We believe the Definiens Developer XD and Tissue Studio software will enable Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays."

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.